Can the BRCA Gene Skip a Generation?

A BRCA1 or BRCA2 mutation does not skip a generation in the way many people fear. These mutations follow standard inheritance rules: a parent who carries one has a 50 percent chance of passing it to each child, every time. What can skip a generation is cancer itself, because not every person who inherits a BRCA mutation develops the disease. That gap between carrying a mutation and actually getting sick creates the illusion of skipping, and it catches families off guard more often than you might expect.

Why Cancer Can Appear to Skip a Generation

The confusion almost always comes down to a concept called incomplete penetrance. “Penetrance” just means the likelihood that someone carrying a mutation will actually develop the associated disease during their lifetime. For BRCA1 and BRCA2, penetrance is high compared to many genetic conditions, but it is far from 100 percent. Estimates for lifetime breast cancer risk in female BRCA1 carriers range from roughly 59 percent to 82 percent depending on the study and the specific mutation type.¹² That means a substantial fraction of women who carry BRCA1 mutations will never be diagnosed with breast or ovarian cancer, even without preventive surgery.

Imagine a grandmother who carried a BRCA1 mutation but never developed cancer. She passes it to her son, who can carry it without any outward sign since male breast cancer linked to BRCA is much rarer. Her son then passes it to his daughter, who is diagnosed at age 40. Looking back at the family tree, the grandmother and son both seemed healthy, and the granddaughter’s cancer appears to have materialized from nowhere. The mutation was present the entire time; the cancer is what skipped.

Research supports this pattern. One study found evidence that common genetic variants may be naturally selected in BRCA1 mutation carrier populations to counteract the cancer-promoting effects of the mutation, contributing to incomplete penetrance.³ In other words, some carriers inherit a kind of biological counterweight alongside the BRCA mutation. They carry the risk gene, but other parts of their genome blunt its impact.

When Fathers Pass It On

The most common reason a BRCA mutation looks like it came out of nowhere is paternal inheritance. People tend to associate BRCA with women’s cancers, so when a father passes a mutation to his daughter, the family history on his side may show no breast or ovarian cancer at all. He might live a perfectly healthy life. His mother, sisters, or aunts who also carried the mutation might have been lucky enough to dodge cancer. The result is a family where the paternal branch looks clean, and the daughter’s diagnosis is a shock.

This is not a rare scenario. A case report documented a paternally inherited BRCA1 mutation associated with an aggressive cancer, noting that loss-of-function mutations can be transmitted from male carriers who are often cancer-free to their daughters, who then face lifetime breast cancer risks potentially as high as 84 percent.⁴ The mutation did not skip the father. He had it. He just never got sick from it, so nobody knew.

A study from JAMA looked at this masking effect more broadly and found that women with limited family structure, particularly limited paternal family structure, were about three times more likely to be BRCA mutation carriers than women with well-documented family histories.⁵ Small families, families with few women on the father’s side, or families where older generations died young from unrelated causes all create blind spots. The mutation is there, but the usual signal, a cluster of cancer diagnoses, never appears.

Carriers With No Obvious Family History

One of the most practical consequences of the “skipping” misconception is that some people assume they do not need genetic testing because no one in their family had cancer. This assumption can be dangerous. A study of Polish breast and ovarian cancer patients found that about 39 percent of BRCA1-positive breast cancer patients and 51 percent of BRCA1-positive ovarian cancer patients had no family history of breast or ovarian cancer among first- and second-degree relatives.⁶ The researchers concluded that breast cancer patients should be evaluated for genetic testing based on clinical and pathological criteria, not just family history alone.

This finding underscores that “no family history” is not the same as “no mutation.” De novo mutations, where a BRCA mutation arises for the first time in a person rather than being inherited, are rare but documented. More commonly, though, the family history simply looks negative because the mutation was traveling silently through male relatives or through female relatives who happened not to develop cancer.

What Influences Whether a Carrier Gets Cancer

If incomplete penetrance explains the apparent skipping, the next question is what determines who among carriers actually develops cancer. The answer involves both genetics and lifestyle, and the research here has matured considerably.

On the genetic side, large international collaborations have confirmed that penetrance varies substantially between studies and between families, consistent with the idea that other genetic variants modify cancer risk in BRCA carriers.⁷ Some of these modifiers are common genetic variants scattered across the genome. Individually, each has a tiny effect, but together they can shift a carrier’s risk meaningfully higher or lower. This is part of why two sisters can carry the same BRCA2 mutation, and one develops cancer in her 30s while the other remains healthy past 70.

Lifestyle and reproductive factors also play a measurable role, particularly for BRCA1 carriers. Across ten studies, late age at first birth, breastfeeding for at least one to two years, and later onset of menstruation were each associated with reductions in breast cancer risk of roughly a third among BRCA1 carriers.⁸ Interestingly, none of these reproductive factors showed a clear association in BRCA2 carriers, suggesting that the two genes interact with hormonal exposures differently.

Oral contraceptive use and smoking have been linked to earlier cancer onset in BRCA mutation carriers. One study found that carriers who used oral contraceptives were diagnosed roughly five years earlier on average than those who did not, and carriers who had been pregnant experienced a later onset than those who had not.⁹ Meanwhile, an Italian cohort study found that higher body fat and having multiple metabolic risk factors were significantly associated with BRCA-related cancer, with a stronger effect in BRCA2-positive women.¹⁰

All of these findings help explain why cancer seems to leap over some family members. A grandmother who carried a BRCA1 mutation, breastfed multiple children, and had a later first period may have had a risk profile that kept cancer at bay. Her granddaughter, living a different life in a different era, faces different modifying factors.

How Cancer Risk Varies by Mutation Type and Location

The specific mutation matters, not just whether you carry one. About 20 percent of hereditary breast cancers are attributable to high-penetrance variants in BRCA1 and BRCA2.¹¹ But within those genes, different mutation locations carry different risk levels. A large study estimated that the overall breast cancer risk for BRCA1 carriers by age 70 was about 59 percent, but for women carrying certain mutation types, like missense mutations or mutations undergoing specific cellular processes, the estimate climbed to 69 percent. The ovarian cancer risk for BRCA1 carriers was about 34 percent overall but dropped to 26 percent for some founder mutations.¹

For BRCA2, the estimated lifetime breast cancer risk by age 70 is around 51 percent, and the ovarian cancer risk is about 11 percent. One widely cited study placed the lifetime breast cancer risk even higher, at 82 percent, in families with many affected members, with ovarian cancer risks of 54 percent for BRCA1 and 23 percent for BRCA2.² The discrepancy between studies is partly because early estimates came from high-risk families where multiple members were affected, which inflated the numbers. More recent population-based studies give somewhat lower figures, but the risk remains substantial by any measure.

Preventive Options for Carriers

Knowing you carry a BRCA mutation opens up options that can dramatically reduce risk. Risk-reducing bilateral mastectomy has been shown to lower mortality from breast cancer, particularly for younger patients. Risk-reducing salpingo-oophorectomy, removal of the fallopian tubes and ovaries, can prevent about 95 percent of BRCA-related ovarian cancers.¹² These are major decisions, and not every carrier chooses surgery. Enhanced surveillance with regular breast MRI and mammography is an alternative, though the evidence that surveillance alone reduces mortality from breast cancer in BRCA carriers is not as clear-cut as the evidence for surgery.

The practical implication for the “skipping” question is this: if someone in your family is a known carrier but you have never been tested, you cannot assume you are safe based on the fact that the carrier never got cancer. The preventive strategies work best when they start early, and that requires knowing your status.

Cascade Testing and Family Communication

When one person in a family tests positive for a BRCA mutation, the recommended next step is cascade testing: systematically offering the same targeted test to blood relatives. Cascade testing is far more efficient than screening the general population because you already know exactly which mutation to look for.¹³

Despite its value, uptake remains low. A large study of over 22,000 individuals with pathogenic variants found that only about 24 percent had at least one family member undergo testing for the same variant. BRCA1 and BRCA2 carriers had slightly higher cascade testing rates, about 27 percent, compared to carriers of other cancer-risk genes.¹⁴ That means roughly three-quarters of families are not following through, leaving relatives unaware of risks they could be managing.

Part of the problem is communication. Disclosing a positive BRCA result to relatives creates ethical tension. Genetic counselors stress the importance of informing at-risk family members, but they also have to respect the patient’s autonomy and confidentiality.¹⁵ Some carriers feel a moral obligation to tell siblings, parents, and cousins. Others are reluctant, whether because of family estrangement, fear of causing anxiety, or cultural norms around discussing health.¹⁶ The result is that information about a potentially life-saving mutation sometimes stays locked in one branch of the family, reinforcing the appearance that cancer struck out of the blue in another branch.

Why Direct-to-Consumer Tests Can Be Misleading

Some people believe they have been tested for BRCA because they used a consumer genetic testing kit. This is a significant source of false reassurance. Most direct-to-consumer tests check only three specific BRCA1/2 mutations that are common in people of Ashkenazi Jewish descent. For people of non-Ashkenazi ancestry, this approach misses more than 90 percent of harmful BRCA1/2 variants. Even among Ashkenazi individuals, about 10 percent of BRCA1/2 mutations are missed.¹⁷ The same study found a false-positive rate of 69 percent for mutations outside the Ashkenazi founder set, meaning the test flagged variants that were not actually pathogenic.

If your family has a history that concerns you, or if you are trying to determine whether a BRCA mutation could have traveled through your family undetected, a consumer test is not sufficient. Clinical-grade testing through a genetics provider examines the full BRCA1 and BRCA2 genes and can detect the wide range of mutations that exist across populations.

Inherited Versus Tumor-Only BRCA Mutations

There is an additional wrinkle that can create confusion in families. Some BRCA mutations are somatic, meaning they arise only in the tumor itself and are not inherited. A woman diagnosed with ovarian cancer might have her tumor tested and learn it carries a BRCA mutation, leading relatives to panic about their own risk. But if the mutation is somatic, it formed during the cancer’s development and cannot be passed to children or siblings.

Distinguishing between inherited (germline) and tumor-only (somatic) mutations requires paired testing, looking at both the tumor and normal tissue like a blood sample. Tumor testing alone can detect both types but cannot tell them apart without that comparison.¹⁸ One study found that about 10 percent of patients tested had somatic BRCA mutations that were absent from their germline.¹⁹ For those individuals, the mutation matters for their own treatment but has no implications for their family.

The Problem of Uncertain Variants

Sometimes genetic testing comes back with a result that is neither clearly positive nor clearly negative: a variant of uncertain significance, or VUS. This means the lab found a change in the BRCA gene but does not yet have enough data to determine whether it increases cancer risk. A VUS result can be especially frustrating in the context of the “skipping” question, because it leaves families unable to know whether they are dealing with a true risk mutation that happened to skip causing cancer, or a benign variant that never mattered in the first place.

The good news is that variants get reclassified over time as more data accumulates. A Turkish cohort study reanalyzed 110 BRCA1 and BRCA2 VUS results and found that 20 percent were reclassified, with about half upgraded to pathogenic or likely pathogenic and the other half downgraded to benign or likely benign.²⁰ If you or a family member received a VUS result, it is worth revisiting with a genetic counselor periodically, as the classification may have changed.

Founder Mutations in Specific Populations

Certain populations carry specific BRCA mutations at much higher rates due to what geneticists call a founder effect, where a mutation present in a small ancestral group becomes common in its descendants. The best-known example is the Ashkenazi Jewish population, where roughly 2 percent carry one of three specific founder mutations in BRCA1 or BRCA2. A study of Ashkenazi women with ovarian cancer found germline mutations in 45 percent, even among women with minimal or no family history.²¹ Notably, the penetrance of these founder mutations was lower than previously estimated when studied in a population-based setting rather than in high-risk families, further supporting the idea that carrying the mutation does not guarantee cancer.

Founder effects are not limited to Ashkenazi populations. Specific BRCA mutations have been identified at elevated frequencies in Icelandic, Norwegian, Dutch, French Canadian, and several other populations. For members of these communities, the “skipping” effect can be even more pronounced: many people in the community carry the mutation, but because it is so common and penetrance is incomplete, cancer appears to strike randomly rather than tracking through families in a recognizable pattern.

Preimplantation Genetic Testing for BRCA

For carriers who want biological children but do not want to pass on their BRCA mutation, preimplantation genetic testing during IVF is an option. This process involves creating embryos through IVF, testing each one for the specific family mutation, and transferring only embryos that did not inherit it. A review of clinical experience from 2010 to 2021 found that most patients in the cohort achieved pregnancy with BRCA-negative embryos.²² Cost-effectiveness analyses have been conducted suggesting that this approach may be economically reasonable given the high downstream costs of BRCA-related cancer treatment and surveillance.²³

This option is worth knowing about because it directly addresses the generation-to-generation transmission question. Rather than hoping the mutation skips your child through luck of inheritance, you can ensure it does not get passed on at all. It requires IVF, which is physically and financially demanding, and it raises its own ethical questions about selecting against a condition where many carriers live long, healthy lives. But for families with histories of aggressive early-onset cancers, it can feel like a way to end the cycle of uncertainty.